172@29@17@107!~!172@29@0@53!~!|news|business|companies|advanced-enzymes-unfazed-by-novozymes-stock-dip-says-biz-strong-973529.html!~!news|moneycontrol|com!~!|controller|infinite_scroll_article.php!~!is_mobile=false
Moneycontrol
Watch experts decode 'The rise of ESG investing' on October 29 at 4pm. Register Now!

business

Advanced Enzymes unfazed by Novozymes stock dip, says biz strong

Speaking to CNBC-TV18, CL Rathi, MD of Advanced Enzymes (AETL) said its misguiding to compare its business with Novozymes. While AETL gets 75 percent of its business from nutrition segment, Novozymes has higher exposure to industrials where input costs are causing pressures.

LATEST VIDEOS

Watch More →

A collection of the most-viewed Moneycontrol videos.

3 Point Analysis

Watch More →

A breakdown of news from business, economy and policy

The vital story of the day and what it really means

Ideas for Profit

Watch More →

Stock insights by our stellar research team

MC Explainer

Watch More →

A collection of analyses that digs deeper into key events

Business Insight

Watch More →

Making sense of events and connecting the dots

In Focus with Udayan Mukherjee

Watch More →

Vital news simplified by our in-house expert

Watch and Follow our leading shows

Sections